Metagenomi, Inc. Common Stock (MGX) financial statements and ratios from SEC XBRL: revenue $25.21M (TTM), net margin -348.5%, revenue growth -51.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $25.21M |
| Net Margin | -348.5% |
| Revenue Growth (YoY) | -51.8% |
| EPS Growth (YoY) | 0.0% |
| FCF Growth (YoY) | -20.3% |
| Price / Book | 0.41 |
| Price / Sales | 3.71 |
| FCF Yield | -323.5% |
| Altman Z-Score | -2.07 (distress) |
| Sector P/E (Healthcare) | 21.7 |
MGX overview · MGX earnings · MGX KPIs · MGX investor relations · MGX ownership · MGX peers · MGX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.